{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:44:43Z","timestamp":1757623483387,"version":"3.44.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00120-025-02659-6","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:46:28Z","timestamp":1755517588000},"page":"976-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuklearmedizinische Optionen bei fortgeschrittenem Prostatakarzinom in der Praxis","Options in nuclear medicine for advanced prostate cancer in practice"],"prefix":"10.1007","volume":"64","author":[{"given":"Sophie Carina","family":"Kunte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp M.","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2659_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2024) S3-Leitlinie Prostatakarzinom, Langversion 7.0, 2024, AWMF-Registernummer:043-022OL. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Prostatatkarzinom\/Version_7\/LL_Prostatakarzinom_Langversion_7.0.pdf"},{"key":"2659_CR2","volume-title":"Epidemiologischer Krebsregister in Deutschland. Prostatakarzinom 2020","author":"RK Gesellschaft","year":"2020","unstructured":"Gesellschaft\u00a0RK (2020) Epidemiologischer Krebsregister in Deutschland. Prostatakarzinom 2020"},{"issue":"10","key":"2659_CR3","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.radcr.2023.07.022","volume":"18","author":"H El Farhaoui","year":"2023","unstructured":"El Farhaoui\u00a0H et\u00a0al (2023) Management of a\u00a0localized prostatic adenocarcinoma despite the very high rate of PSA and the large tumor mass: Does PSA level indicate the stage of prostate cancer? Radiol Case Rep 18(10):3501\u20133503","journal-title":"Radiol Case Rep"},{"issue":"17","key":"2659_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2024.4011","volume":"331","author":"RM Martin","year":"2024","unstructured":"Martin\u00a0RM et\u00a0al (2024) Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A\u00a0Secondary Analysis of the CAP Randomized Clinical Trial. JAMA 331(17):1460\u20131470","journal-title":"JAMA"},{"issue":"11","key":"2659_CR5","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita\u00a0A et\u00a0al (2022) Novel Framework for Treatment Response Evaluation Using PSMA PET\/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J\u00a0Nucl Med 63(11):1651\u20131658","journal-title":"J Nucl Med"},{"issue":"6","key":"2659_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.eururo.2017.11.030","volume":"73","author":"S Eggener","year":"2018","unstructured":"Eggener\u00a0S (2018) Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol 73(6):897\u2013898","journal-title":"Eur Urol"},{"issue":"1","key":"2659_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13059-016-1129-3","volume":"18","author":"K Mundbjerg","year":"2017","unstructured":"Mundbjerg\u00a0K et\u00a0al (2017) Identifying aggressive prostate cancer foci using a\u00a0DNA methylation classifier. Genome Biol 18(1):3","journal-title":"Genome Biol"},{"issue":"6","key":"2659_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang\u00a0AJ et\u00a0al (2014) High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 11(6):308\u2013323","journal-title":"Nat Rev Clin Oncol"},{"key":"2659_CR9","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2025) Langversion 8.0, 2025, AWMF-Registernummer: 043-022OL. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/;"},{"issue":"11","key":"2659_CR10","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1007\/s00259-017-3752-y","volume":"44","author":"C \u00d6bek","year":"2017","unstructured":"\u00d6bek\u00a0C et\u00a0al (2017) The accuracy of (68)Ga-PSMA PET\/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 44(11):1806\u20131812","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2659_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/1450-1147.207272","volume":"16","author":"M Gupta","year":"2017","unstructured":"Gupta\u00a0M et\u00a0al (2017) A\u00a0Comparative Study of (68)Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience. World J Nucl Med 16(3):186\u2013191","journal-title":"World J Nucl Med"},{"issue":"2","key":"2659_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bju.13987","volume":"121","author":"AP Kenigsberg","year":"2018","unstructured":"Kenigsberg\u00a0AP et\u00a0al (2018) Multiparametric magnetic resonance imaging identifies significant apical prostate cancers. BJU Int 121(2):239\u2013243","journal-title":"BJU Int"},{"key":"2659_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00261-015-0579-5","volume":"41","author":"RT Gupta","year":"2016","unstructured":"Gupta\u00a0RT et\u00a0al (2016) Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer. Abdom Radiol 41:831\u2013843","journal-title":"Abdom Radiol"},{"issue":"1","key":"2659_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0284185114561915","volume":"57","author":"J Nowak","year":"2016","unstructured":"Nowak\u00a0J et\u00a0al (2016) The value of ADC, T2 signal intensity, and a\u00a0combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer. Acta Radiol 57(1):107\u2013114","journal-title":"Acta Radiol"},{"issue":"10071","key":"2659_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed\u00a0HU et\u00a0al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a\u00a0paired validating confirmatory study. Lancet 389(10071):815\u2013822","journal-title":"Lancet"},{"issue":"4","key":"2659_CR16","first-page":"Cd012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost\u00a0FH et\u00a0al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4(4):Cd12663","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2659_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/bju.15065","volume":"126","author":"DF Osses","year":"2020","unstructured":"Osses\u00a0DF et\u00a0al (2020) Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary? BJU Int 126(1):124\u2013132","journal-title":"BJU Int"},{"issue":"2","key":"2659_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0094-0143(02)00184-2","volume":"30","author":"RS Purohit","year":"2003","unstructured":"Purohit\u00a0RS et\u00a0al (2003) Imaging clinically localized prostate cancer. Urol Clin North Am 30(2):279\u2013293","journal-title":"Urol Clin North Am"},{"key":"2659_CR19","doi-asserted-by":"publisher","first-page":"109556","DOI":"10.1016\/j.ejrad.2021.109556","volume":"136","author":"J Morawitz","year":"2021","unstructured":"Morawitz\u00a0J et\u00a0al (2021) PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur J Radiol 136:109556","journal-title":"Eur J Radiol"},{"issue":"9","key":"2659_CR20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","volume":"43","author":"T Van den Wyngaert","year":"2016","unstructured":"Van den Wyngaert\u00a0T et\u00a0al (2016) The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 43(9):1723\u20131738","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2659_CR21","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","volume":"171","author":"S Abuzallouf","year":"2004","unstructured":"Abuzallouf\u00a0S, Dayes\u00a0I, Lukka\u00a0H (2004) Baseline staging of newly diagnosed prostate cancer: a\u00a0summary of the literature. J\u00a0Urol 171(6):2122\u20132127","journal-title":"J Urol"},{"issue":"2","key":"2659_CR22","first-page":"287","volume":"47","author":"E Even-Sapir","year":"2006","unstructured":"Even-Sapir\u00a0E et\u00a0al (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT. J\u00a0Nucl Med 47(2):287\u2013297","journal-title":"J Nucl Med"},{"issue":"6","key":"2659_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/RLU.0b013e3181db4bba","volume":"35","author":"A Sood","year":"2010","unstructured":"Sood\u00a0A, Sethi\u00a0S, Kumar\u00a0R (2010) Tracheal uptake on Tc-99m MDP bone scintigraphy can be a\u00a0potential source of false-positive results in a\u00a0prostate cancer patient. Clin Nucl Med 35(6):454\u2013455","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2659_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.semnuclmed.2023.07.004","volume":"54","author":"N Mohseninia","year":"2024","unstructured":"Mohseninia\u00a0N et\u00a0al (2024) Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging. Semin Nucl Med 54(1):97\u2013118","journal-title":"Semin Nucl Med"},{"key":"2659_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-50468-0","volume-title":"MR-und PET-Bildgebung der Prostata","author":"U Attenberger","year":"2017","unstructured":"Attenberger\u00a0U, Ritter\u00a0M, Wenz\u00a0F (2017) MR-und PET-Bildgebung der Prostata. Springer"},{"issue":"14","key":"2659_CR26","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1128\/MCB.00084-06","volume":"26","author":"RE Conway","year":"2006","unstructured":"Conway\u00a0RE et\u00a0al (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26(14):5310\u20135324","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2659_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber\u00a0M et\u00a0al (2016) Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 70(5):829\u2013836","journal-title":"Eur Urol"},{"issue":"5","key":"2659_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer\u00a0T et\u00a0al (2016) Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J\u00a0Urol 195(5):1436\u20131443","journal-title":"J Urol"},{"issue":"10231","key":"2659_CR29","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a\u00a0prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"issue":"12","key":"2659_CR30","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka\u00a0T et\u00a0al (2016) Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43(12):2114\u20132121","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2659_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3413\/Nukmed-0846-16-09","volume":"56","author":"A Br\u00e4uer","year":"2017","unstructured":"Br\u00e4uer\u00a0A et\u00a0al (2017) Diagnostic value of additional (68)Ga-PSMA-PET before (223)Ra-dichloride therapy in patients with metastatic prostate carcinoma. Nuklearmedizin 56(1):14\u201322","journal-title":"Nuklearmedizin"},{"key":"2659_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner\u00a0S et\u00a0al (2020) Automated production of [(18)F]SiTATE on a\u00a0Scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors. Nucl Med Biol 88\u201389:86\u201395","journal-title":"Nucl Med Biol"},{"issue":"1","key":"2659_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu\u00a0CE et\u00a0al (2024) Evaluating the biodistribution for [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res 14(1):36","journal-title":"EJNMMI Res"},{"issue":"4","key":"2659_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James\u00a0ND et\u00a0al (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N\u00a0Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"8","key":"2659_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney\u00a0CJ et\u00a0al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N\u00a0Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"5","key":"2659_CR36","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert\u00a0R et\u00a0al (2023) Unspecific (18)F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. J\u00a0Nucl Med 64(5):738\u2013743","journal-title":"J Nucl Med"},{"key":"2659_CR37","unstructured":"Bundesvereinigung K (2023) https:\/\/www.kbv.de\/media\/sp\/EBM_2023-10-01_BA_676_BeeG_Pluvicto.pdf. Zugegriffen: 13. Aug. 2024"},{"issue":"1","key":"2659_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/pros.23919","volume":"80","author":"B Grubm\u00fcller","year":"2020","unstructured":"Grubm\u00fcller\u00a0B et\u00a0al (2020) Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 80(1):74\u201382","journal-title":"Prostate"},{"issue":"1","key":"2659_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.110.077941","volume":"52","author":"H Jadvar","year":"2011","unstructured":"Jadvar\u00a0H (2011) Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J\u00a0Nucl Med 52(1):81\u201389","journal-title":"J Nucl Med"},{"issue":"1","key":"2659_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-015-0038-0","volume":"15","author":"JM Beauregard","year":"2015","unstructured":"Beauregard\u00a0JM et\u00a0al (2015) FDG-PET\/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging 15(1):2","journal-title":"Cancer Imaging"},{"key":"2659_CR41","doi-asserted-by":"crossref","unstructured":"Quiros-Gonzalez I et\u00a0al (2022) Androgen-Dependent Prostate Cancer Cells Reprogram Their Metabolic Signature upon GLUT1 Upregulation by Manganese Superoxide Dismutase. Antioxidants (basel) 11(2)","DOI":"10.3390\/antiox11020313"},{"issue":"6","key":"2659_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00259-023-06585-7","volume":"51","author":"J Kim","year":"2024","unstructured":"Kim\u00a0J et\u00a0al (2024) Combination of [(18)F]FDG and [(18)F]PSMA-1007 PET\/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer. Eur J Nucl Med Mol Imaging 51(6):1763\u20131772","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2659_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","volume":"54","author":"DEK Sutherland","year":"2024","unstructured":"Sutherland\u00a0DEK et\u00a0al (2024) Role of FDG PET\/CT in Management of Patients with Prostate Cancer. Semin Nucl Med 54(1):4\u201313","journal-title":"Semin Nucl Med"},{"issue":"9","key":"2659_CR44","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt\u00a0MF et\u00a0al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44(9):1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2659_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/039463201002300213","volume":"23","author":"D Morichetti","year":"2010","unstructured":"Morichetti\u00a0D et\u00a0al (2010) Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol 23(2):511\u2013522","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2659_CR46","doi-asserted-by":"crossref","unstructured":"Bilen MA et\u00a0al (2022) Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT. Cancers (basel) 14(24)","DOI":"10.3390\/cancers14246039"},{"issue":"12","key":"2659_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","volume":"44","author":"E Panagiotidis","year":"2023","unstructured":"Panagiotidis\u00a0E et\u00a0al (2023) Comparison of 18F-PSMA-1007 and 18F-Choline PET\/CT in prostate cancer patients with biochemical recurrence: a\u00a0phase\u00a03, prospective, multicenter, randomized study. Nucl Med Commun 44(12):1126\u20131134","journal-title":"Nucl Med Commun"},{"issue":"1","key":"2659_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","volume":"44","author":"J Schwenck","year":"2017","unstructured":"Schwenck\u00a0J et\u00a0al (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET\/CT. Eur J Nucl Med Mol Imaging 44(1):92\u2013101","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2659_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.117.196444","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais\u00a0J, Cao\u00a0M, Nickols\u00a0NG (2018) The Utility of PET\/CT in the Planning of External Radiation Therapy for Prostate Cancer. J\u00a0Nucl Med 59(4):557\u2013567","journal-title":"J Nucl Med"},{"issue":"3","key":"2659_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker\u00a0C et\u00a0al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"key":"2659_CR51","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/DDDT.S122417","volume":"11","author":"E Deshayes","year":"2017","unstructured":"Deshayes\u00a0E et\u00a0al (2017) Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther 11:2643\u20132651","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"2659_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","volume":"73","author":"CC Parker","year":"2018","unstructured":"Parker\u00a0CC et\u00a0al (2018) Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase\u00a03 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol 73(3):427\u2013435","journal-title":"Eur Urol"},{"issue":"3","key":"2659_CR53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith\u00a0M et\u00a0al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Oncol 20(3):408\u2013419","journal-title":"Lancet Oncol"},{"issue":"3","key":"2659_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber\u00a0M et\u00a0al (2018) Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT. J\u00a0Nucl Med 59(3):469\u2013478","journal-title":"J Nucl Med"},{"issue":"12","key":"2659_CR55","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O et\u00a0al (2021) Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N\u00a0Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"key":"2659_CR56","doi-asserted-by":"crossref","unstructured":"Hennrich U, Eder M (2022) 177 Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharm (basel) 15(10)","DOI":"10.3390\/ph15101292"},{"issue":"9","key":"2659_CR57","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah\u00a0J et\u00a0al (2023) FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 29(9):1651\u20131657","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2659_CR58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","volume":"26","author":"SJ Keam","year":"2022","unstructured":"Keam\u00a0SJ (2022) Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. Mol Diagn Ther 26(4):467\u2013475","journal-title":"Mol Diagn Ther"},{"key":"2659_CR59","unstructured":"(2016) Therpaie mit Lu-177-PSMA, Dosimetrie und Nachsorge beim metastasierten, kastrationsresistenten Prostatakarzinom. https:\/\/www.nuklearmedizin.de\/docs\/Lu-177-PSMA_160224.pdf"},{"issue":"8","key":"2659_CR60","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt\u00a0C et\u00a0al (2022) Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. J\u00a0Nucl Med 63(8):1199\u20131207","journal-title":"J Nucl Med"},{"issue":"5","key":"2659_CR61","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil\u00a0C et\u00a0al (2018) Targeted \u03b1\u2011therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J\u00a0Nucl Med 59(5):795\u2013802","journal-title":"J Nucl Med"},{"issue":"2","key":"2659_CR62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge\u00a0MM et\u00a0al (2024) Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a\u00a0multicentre, retrospective study. Lancet Oncol 25(2):175\u2013183","journal-title":"Lancet Oncol"},{"issue":"6","key":"2659_CR63","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","volume":"13","author":"R Eychenne","year":"2021","unstructured":"Eychenne\u00a0R et\u00a0al (2021) Overview of the most promising radionuclides for targeted alpha therapy: The \u201chopeful eight\u201d. Pharmaceutics 13(6):906","journal-title":"Pharmaceutics"},{"issue":"5","key":"2659_CR64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","volume":"28","author":"B Ramnaraign","year":"2023","unstructured":"Ramnaraign\u00a0B, Sartor\u00a0O (2023) PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. Oncologist 28(5):392\u2013401","journal-title":"Oncologist"},{"issue":"5","key":"2659_CR65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-022-06092-1","volume":"50","author":"A Delker","year":"2023","unstructured":"Delker\u00a0A et\u00a0al (2023) Biodistribution and dosimetry for combined [ 177 Lu]Lu-PSMA-I&T\/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging 50(5):1280\u20131290","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2659_CR66","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett\u00a0L et\u00a0al (2024) 177 Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase\u00a02\u00a0trial. Lancet Oncol 25(5):563\u2013571","journal-title":"Lancet Oncol"},{"issue":"10459","key":"2659_CR67","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris\u00a0MJ et\u00a0al (2024) 177 Lu-PSMA-617 versus a\u00a0change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a\u00a0phase\u00a03, randomised, controlled trial. Lancet 404(10459):1227\u20131239","journal-title":"Lancet"},{"key":"2659_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","volume":"75","author":"LM Unterrainer","year":"2024","unstructured":"Unterrainer\u00a0LM, Calais\u00a0J, Bander\u00a0NH (2024) Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annu Rev Med 75:49\u201366","journal-title":"Annu Rev Med"},{"issue":"10","key":"2659_CR69","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad\u00a0AA et\u00a0al (2024) Sequential [ 177 Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a\u00a0multicentre, open-label, randomised, phase\u00a02\u00a0study. Lancet Oncol 25(10):1267\u20131276","journal-title":"Lancet Oncol"},{"issue":"4","key":"2659_CR70","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2967\/jnumed.123.266268","volume":"65","author":"D Hardiansyah","year":"2024","unstructured":"Hardiansyah\u00a0D et\u00a0al (2024) Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [ 177 Lu]Lu-PSMA-617 Therapy. J\u00a0Nucl Med 65(4):566\u2013572","journal-title":"J Nucl Med"},{"issue":"1","key":"2659_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-024-01094-6","volume":"14","author":"H Li","year":"2024","unstructured":"Li\u00a0H et\u00a0al (2024) Biodistribution and dosimetry of 177 Lu-DOTA-IBA for therapy of bone metastases. EJNMMI Res 14(1):30","journal-title":"EJNMMI Res"},{"issue":"3","key":"2659_CR72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen\u00a0RS et\u00a0al (2024) Administering [ 177 Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A\u00a0Single-centre, Single-arm, Phase\u00a01\/2\u00a0Study. Eur Urol 85(3):217\u2013226","journal-title":"Eur Urol"},{"key":"2659_CR73","doi-asserted-by":"crossref","unstructured":"Rosar F et\u00a0al (2022) Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. Cancers (basel) 14(7)","DOI":"10.3390\/cancers14071696"},{"issue":"1","key":"2659_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40658-024-00636-0","volume":"11","author":"D Grob","year":"2024","unstructured":"Grob\u00a0D et\u00a0al (2024) Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT\/CT. EJNMMI Phys 11(1):34","journal-title":"EJNMMI Phys"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02659-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:22:46Z","timestamp":1757398966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02659-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2659"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02659-6","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"6 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"S.C.\u00a0Kunte: A.\u00a0Finanzielle Interessen: S.\u00a0C. Kunte gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte \u00c4rztin, LMU-Klinikum der Universit\u00e4t M\u00fcnchen; Angestellte \u00c4rztin, Diabetes\u2011, Hormon- und Stoffwechselzentrum am Isarklinikum M\u00fcnchen. L.M.\u00a0Unterrainer: A.\u00a0Finanzielle Interessen: Bayerisches Zentrum f\u00fcr Krebsforschung (BZKF)\u00a0\u2013 Young Scientist Fellowship: Personal, Munich Clinican Scientist Program (MCSP) der LMU M\u00fcnchen: Personal | Lena Unterrainer reports fees from Novartis (speaker), Telix (consultant, travel) and Astellas Pharma Inc. (speaker) outside of the submitted work | Telix (consultant).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: TU M\u00fcnchen, Klinik f\u00fcr Nuklearmedizin, Ober\u00e4rztin; LMU M\u00fcnchen, Klinik f\u00fcr Nuklearmedizin, Gastwissenschaftlerin | UCLA: Visiting Assistant Professor; ESHI Society: Chair of Research Commitee | Mitgliedschaften: EANM, DGN, BGN. P.\u00a0Kazmierczak: A.\u00a0Finanzielle Interessen: Vortragshonorar Bracco Imaging Deutschland GmbH.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt und Bereichsleiter Urologische Bildgebung, LMU-Klinikum, M\u00fcnchen | Mitglied der AG Uroradiologie und Urogenitaldiagnostik der Deutschen R\u00f6ntgengesellschaft. A.\u00a0Holzgreve: A.\u00a0Finanzielle Interessen: Adrien Holzgreve wurde gef\u00f6rdert durch die Deutsche Forschungsgemeinschaft (DFG; 545058105) und das Bayerische Zentrum f\u00fcr Krebsforschung (BZKF)\u00a0\u2013 Honorar f\u00fcr wissenschaftliche Beratung von ABX advanced biochemical compounds.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt LMU Klinik und Poliklinik f\u00fcr Nuklearmedizin. C.\u00a0Stief: A.\u00a0Finanzielle Interessen: C.\u00a0Stief gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Klinikdirektor | Mitglied im Wissenschaftsrat, Mitglied der Leopoldina. J.\u00a0Casuscelli: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Bayer, Astellas, Johnson&Johnson, Ipsen, MSD, Astra Zeneca\u00a0\u2013 bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: MSD.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Ober\u00e4rztin an der Urologischen Klinik und Poliklinik der Universit\u00e4t M\u00fcnchen | Mitgliedschaften: DGU, EAU, ESMO, AUO, DKG. M.\u00a0Unterrainer: A.\u00a0Finanzielle Interessen: M.\u00a0Unterrainer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: niedergelassen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}